EHA 2024 Insights: Intrathecal Rituximab + Dex for Refractory Sanctuary CNS Involvement in B-Cell Malignancies

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

EHA 2024 Insights: Intrathecal Rituximab + Dex for Refractory Sanctuary CNS Involvement in B-Cell Malignancies

By Insights from 2024 EHA Annual Meeting FEATURING Maher Salamoon

98 views

July 9, 2024

0 Comments

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale

16:57

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Lymphoma Highlights"

Feat. B. D. Cheson

22:37

Insights from 2023 ASH Annual Meeting

AML and MDS Highlights & Key Takeaways

Feat. T. Badar

22:11

SOHO Brazil 2024

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

Feat. A. Zelenetz

13:07

Moffitt Cancer Center

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Feat. J. Chavez

22:09

Scripps Health

New Updates in Frontline DLBCL

Feat. L. Nastoupil

27:47

Indy Hematology Review

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Feat. S. Smith

22:29

SOHO Brazil 2024

1L Therapy in CLL: What Are the Best Options?

Feat. J. Burger

12:47

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Experts Discuss Key Abstracts in CLL"

Feat. S. O'Brien, C. Coombs

09:51

i3 Health

MRD Testing in Leukemias: When Negativity Is a Positive Thing

Feat. N. S. Raje

17:05

Cleveland Clinic Taussig Cancer Institute

Frontline CLL Learnings From Phase 3 RESONATE-2, iLLUMINATE, and E19…

Feat. A. Winter

24:44

Indy Hematology Review

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Feat. R. Birhiray

35:12

Integrity CE

Clinical Practice Updates in CLL/SLL

Feat. M. Cortese, D. Wallace, A. Niu

08:18

Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou

08:47

Sarah Tasian

Recent Updates on Blinatumomab in ALL: FDA Approval in 1L and Incorp…

06:33

Christopher Flowers

FDA Approval of Zanubrutinib in R/R FL: What You Need to Know

35:27

Louisville Hematology Highlights

Updates on Management of DLBCL

Feat. J. Leonard

03:06

City of Hope

CLL Treatment Sequencing: The Importance of First Choice

Feat. S. Rosen

16:16

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

Overview of CNS Cancers

Feat. V. Venur

04:04

Wojciech Jurczak

Login

Login

Join VuMedi

EHA 2024 Insights: Intrathecal Rituximab + Dex for Refractory Sanctuary CNS Involvement in B-Cell Malignancies

Related Content